Breaking News Instant updates and real-time market news.

LLY

Eli Lilly

$75.95

0.69 (0.92%)

, TEVA

Teva

$34.23

-0.05 (-0.15%)

10:12
01/12/17
01/12
10:12
01/12/17
10:12

Eli Lilly wins Alimta patent appeal against Teva, Bloomberg reports

LLY

Eli Lilly

$75.95

0.69 (0.92%)

TEVA

Teva

$34.23

-0.05 (-0.15%)

  • 19

    Jan

  • 31

    Jan

  • 12

    Feb

  • 21

    Feb

LLY Eli Lilly
$75.95

0.69 (0.92%)

12/19/16
JEFF
12/19/16
DOWNGRADE
Target $48
JEFF
Underperform
Merck downgraded to Underperform from Hold at Jefferies
Jefferies analyst Jeffrey Holford downgraded Merck (MRK) to Underperform, his firm's sell-rating equivalent. The analyst sees Pharmaceutical sector fundamentals weakening in 2017 amid political overhangs and an adverse macro environment. Potential dual eligible rebate reform is the most significant risk, Holford tells investors in a research note. Specific to Merck, the analyst expects further pressure on Keytruda in 2018, driven by share losses in non-small cell lung cancer to Bristol-Myers Squibb (BMY), AstraZeneca (AZN) and Roche (RHHBY). Merck screens poorly on many valuation metrics, Holford contends. He lowered his price target for the shares to $48 from $59. The stock closed Friday up 7c to $62.44. The analyst this morning also upgraded both Bristol-Myers Squibb (BMY) and Bayer (BAYRY) to Buy from Hold. His top picks in Pharmaceuticals are AbbVie (ABBV) and Eli Lilly (LLY) for the U.S. and AstraZeneca and Novartis (NVS) in Europe.
12/20/16
FBCO
12/20/16
NO CHANGE
FBCO
Eli Lilly removed from the US Focus List at Credit Suisse
12/21/16
PIPR
12/21/16
NO CHANGE
PIPR
Piper lays out top BioPharma picks for 2017
Piper Jaffray analysts laid out their top BioPharma picks for 2017. Analyst Richard Purkiss favors Pfizer (PFE) and Eli Lilly (LLY) as his top large pharma picks. Analyst Joshua Schimmer calls Gilead (GILD) and Alexion (ALXN) his top large cap picks. Analyst David Amsellem names Horizon Pharma (HZNP) his top specialty pharma pick. Piper's other top Biopharma picks for 2017 include ACADIA (ACAD), Aimmune (AIMT), Akorn (AKRX), Alnylam (ALNY), Axovant Sciences (AXON), Cara Therapeutics (CARA), CoLucid Pharmaceuticals (CLCD), Eale Pharmaceuticals (EGRX), Exelixis (EXEL), Ionis Pharmaceuticals (IONS), Mallinckrodt (MNK), Neurocrine (NBIX), Nektar (NKTR), Otonomy (OTIC), Reata Pharmaceuticals (RETA), Rigel Pharmaceuticals (RIGL), Ignyta (RXDX), Theravance Biopharma (TBPH), Versartis (VSAR) and Voyager Therapeutics (VYGR). The analysts look for recent momentum in BioPharma to continue in 2017. They believe innovation and potentially repatriation should lead to increased merger activity.
01/09/17
PIPR
01/09/17
NO CHANGE
PIPR
Piper lists Pfizer, Lilly as top 2017 large-cap Pharma picks
Piper Jaffray analyst Richard Purkiss highlights Pfizer (PFE) and Eli Lilly (LLY) as his top large-cap Pharma picks in 2017,saying he prefers "cheaper growth names with limited event risk." With group earnings growth set to halve in 2017 as pipeline momentum stalls, the analyst sees "little likelihood" of sector outperformance. Purkiss calls Merck (MRK) and Johnson & Johnson (JNJ) his least preferred names in large-cap Pharma.
TEVA Teva
$34.23

-0.05 (-0.15%)

01/09/17
RBCM
01/09/17
NO CHANGE
RBCM
Teva price target lowered to $42 from $51 at RBC Capital
RBC Capital analyst Randall Stanicky lowered his price target on Teva after the company's business outlook update. The analyst now believes that the company's earnings will not meet expectations and its stock will not rise unless the generic version of three times per week Copaxone is delayed. Stanicky believes that Street estimates for Teva are too high. However, he remains upbeat on the longer term outlook of its specialty business and keeps an Outperform rating on the shares.
01/09/17
WELS
01/09/17
DOWNGRADE
WELS
Market Perform
Teva downgraded to Market Perform from Outperform at Wells Fargo
Wells Fargo analyst David Maris downgraded Teva (TEVA) to Market Perform from Outperform stating that the company's earnings guidance cut is just the latest in a series of disappointments, which also included the SD809 delay, a key executive departure, the Rimsa deal and the Regeneron (REGN) deals. While acknowledging it is possible he is downgrading at a bottom, given that Teva estimates it has approximately $10B of ratings sensitive debt, Maris believes downside risks still exist. He lowered his price target range on Teva shares to $37-$38 from $51-$53.
01/09/17
COWN
01/09/17
NO CHANGE
Target $50
COWN
Outperform
Teva price target lowered to $50 from $100 at Cowen
Cowen analyst Ken Cacciatore lowered his price target on Teva to $50 from $100 after the company released updated financial guidance for 2017. The analyst maintained his Outperform rating on the belief that very few unknowns remain, but said management needs to execute, realize cost reductions, generate cash, and pay down debt.
01/12/17
WBLR
01/12/17
NO CHANGE
WBLR
Outperform
Eagle Pharmaceuticals recent selloff overdone, says William Blair
William Blair analyst Tim Lugo views the 26% selloff in shares of Eagle Pharmaceuticals (EGRX) since marketing partner Teva (TEVA) issued 2017 financial guidance as overdone. Teva's outlook included a range of $600M-$660M for Bendeka/Treanda, which reflects expectations of a mid-single-digit volume decrease and no price offsets. The range was below Lugo's expectations by 13%-21%. While negative growth in Bendeka is concerning, with modest pipeline execution, Eagle's shares could see "significant" price appreciation by the end of 2017, Lugo tells investors in a research note. He keeps an Outperform rating on the shares.

TODAY'S FREE FLY STORIES

AMZN

Amazon.com

$1,168.92

6.92 (0.60%)

05:24
12/12/17
12/12
05:24
12/12/17
05:24
Hot Stocks
AWS, NWCD announce second AWS region in China now available to customers »

Amazon Web Services, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Mar

SAIL

SailPoint Technologies

$14.83

-0.61 (-3.95%)

05:23
12/12/17
12/12
05:23
12/12/17
05:23
Initiation
SailPoint Technologies initiated  »

SailPoint Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GTY

Getty Realty

$28.10

0.08 (0.29%)

05:22
12/12/17
12/12
05:22
12/12/17
05:22
Initiation
Getty Realty initiated  »

Getty Realty initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MNK

Mallinckrodt

$23.14

0.84 (3.77%)

05:16
12/12/17
12/12
05:16
12/12/17
05:16
Recommendations
Mallinckrodt analyst commentary  »

Mallinckrodt management…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

SFIX

Stitch Fix

$23.98

0.38 (1.61%)

05:13
12/12/17
12/12
05:13
12/12/17
05:13
Initiation
Stitch Fix initiated  »

Stitch Fix initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Dec

WEB

Web.com

$23.00

1.2 (5.50%)

05:10
12/12/17
12/12
05:10
12/12/17
05:10
Downgrade
Web.com rating change  »

Web.com downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNPS

Synopsys

$89.56

-0.95 (-1.05%)

05:09
12/12/17
12/12
05:09
12/12/17
05:09
Downgrade
Synopsys rating change  »

Synopsys downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SSNC

SS&C

$41.38

0.75 (1.85%)

05:09
12/12/17
12/12
05:09
12/12/17
05:09
Downgrade
SS&C rating change  »

SS&C downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NOW

ServiceNow

$123.09

1.28 (1.05%)

05:08
12/12/17
12/12
05:08
12/12/17
05:08
Downgrade
ServiceNow rating change  »

ServiceNow downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

RNG

RingCentral

$47.55

-0.75 (-1.55%)

05:08
12/12/17
12/12
05:08
12/12/17
05:08
Downgrade
RingCentral rating change  »

RingCentral downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QTWO

Q2 Holdings

$40.35

-0.1 (-0.25%)

05:07
12/12/17
12/12
05:07
12/12/17
05:07
Downgrade
Q2 Holdings rating change  »

Q2 Holdings downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

QLYS

Qualys

$59.00

0.55 (0.94%)

05:07
12/12/17
12/12
05:07
12/12/17
05:07
Downgrade
Qualys rating change  »

Qualys downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PTC

PTC

$61.44

-0.26 (-0.42%)

05:06
12/12/17
12/12
05:06
12/12/17
05:06
Downgrade
PTC rating change  »

PTC downgraded to Neutral…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NEWR

New Relic

$60.00

2.77 (4.84%)

05:06
12/12/17
12/12
05:06
12/12/17
05:06
Downgrade
New Relic rating change  »

New Relic downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

TYPE

Monotype Imaging

$24.40

-0.2 (-0.81%)

05:05
12/12/17
12/12
05:05
12/12/17
05:05
Downgrade
Monotype Imaging rating change  »

Monotype Imaging…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MODN

Model N

$16.00

0.05 (0.31%)

05:05
12/12/17
12/12
05:05
12/12/17
05:05
Downgrade
Model N rating change  »

Model N downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MIME

Mimecast

$28.02

-0.72 (-2.51%)

05:04
12/12/17
12/12
05:04
12/12/17
05:04
Downgrade
Mimecast rating change  »

Mimecast downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IMPV

Imperva

$41.85

0.3 (0.72%)

05:04
12/12/17
12/12
05:04
12/12/17
05:04
Downgrade
Imperva rating change  »

Imperva downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GDDY

GoDaddy

$48.95

0.07 (0.14%)

05:03
12/12/17
12/12
05:03
12/12/17
05:03
Downgrade
GoDaddy rating change  »

GoDaddy downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FTNT

Fortinet

$42.22

0.27 (0.64%)

05:02
12/12/17
12/12
05:02
12/12/17
05:02
Downgrade
Fortinet rating change  »

Fortinet downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 17

    Jan

CSGP

CoStar Group

$290.50

-1.84 (-0.63%)

05:02
12/12/17
12/12
05:02
12/12/17
05:02
Downgrade
CoStar Group rating change  »

CoStar Group downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

  • 15

    Dec

  • 26

    Feb

CHKP

Check Point

$105.85

1.07 (1.02%)

05:01
12/12/17
12/12
05:01
12/12/17
05:01
Downgrade
Check Point rating change  »

Check Point downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

CUDA

Barracuda

$27.61

0.08 (0.29%)

05:00
12/12/17
12/12
05:00
12/12/17
05:00
Downgrade
Barracuda rating change  »

Barracuda downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADBE

Adobe

$174.31

0.74 (0.43%)

04:59
12/12/17
12/12
04:59
12/12/17
04:59
Downgrade
Adobe rating change  »

Adobe downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

SAIL

SailPoint Technologies

$14.83

-0.61 (-3.95%)

04:56
12/12/17
12/12
04:56
12/12/17
04:56
Initiation
SailPoint Technologies initiated  »

SailPoint Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.